Cargando…
Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009
BACKGROUND: U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remai...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832515/ https://www.ncbi.nlm.nih.gov/pubmed/24260137 http://dx.doi.org/10.1371/journal.pone.0078952 |
_version_ | 1782291696483041280 |
---|---|
author | Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Collier, Ann Samji, Hasina Thorne, Jennifer E. Althoff, Keri N. Martin, Jeffrey N. Rodriguez, Benigno Stuart, Elizabeth A. Gange, Stephen J. |
author_facet | Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Collier, Ann Samji, Hasina Thorne, Jennifer E. Althoff, Keri N. Martin, Jeffrey N. Rodriguez, Benigno Stuart, Elizabeth A. Gange, Stephen J. |
author_sort | Hanna, David B. |
collection | PubMed |
description | BACKGROUND: U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes. METHODS: We analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a first reported CD4+ <350 cells/uL or AIDS-defining illness) from 14 U.S. cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Using propensity score matching and Cox regression, we assessed ART initiation (within 6 months following eligibility) and virologic suppression (within 1 year) based on differences in two state ADAP features: the amount of state funding in annual ADAP budgets and the implementation of waiting lists. We performed an a priori subgroup analysis in persons with a history of injection drug use (IDU). RESULTS: Among 8,874 persons, 56% initiated ART within six months following eligibility. Persons living in states with no additional state contribution to the ADAP budget initiated ART on a less timely basis (hazard ratio [HR] 0.73, 95% CI 0.60–0.88). Living in a state with an ADAP waiting list was not associated with less timely initiation (HR 1.12, 95% CI 0.87–1.45). Neither additional state contributions nor waiting lists were significantly associated with virologic suppression. Persons with an IDU history initiated ART on a less timely basis (HR 0.67, 95% CI 0.47–0.95). CONCLUSIONS: We found that living in states that did not contribute additionally to the ADAP budget was associated with delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued assessment of the role of ADAPs and their features that facilitate prompt treatment is needed. |
format | Online Article Text |
id | pubmed-3832515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38325152013-11-20 Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Collier, Ann Samji, Hasina Thorne, Jennifer E. Althoff, Keri N. Martin, Jeffrey N. Rodriguez, Benigno Stuart, Elizabeth A. Gange, Stephen J. PLoS One Research Article BACKGROUND: U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes. METHODS: We analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a first reported CD4+ <350 cells/uL or AIDS-defining illness) from 14 U.S. cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Using propensity score matching and Cox regression, we assessed ART initiation (within 6 months following eligibility) and virologic suppression (within 1 year) based on differences in two state ADAP features: the amount of state funding in annual ADAP budgets and the implementation of waiting lists. We performed an a priori subgroup analysis in persons with a history of injection drug use (IDU). RESULTS: Among 8,874 persons, 56% initiated ART within six months following eligibility. Persons living in states with no additional state contribution to the ADAP budget initiated ART on a less timely basis (hazard ratio [HR] 0.73, 95% CI 0.60–0.88). Living in a state with an ADAP waiting list was not associated with less timely initiation (HR 1.12, 95% CI 0.87–1.45). Neither additional state contributions nor waiting lists were significantly associated with virologic suppression. Persons with an IDU history initiated ART on a less timely basis (HR 0.67, 95% CI 0.47–0.95). CONCLUSIONS: We found that living in states that did not contribute additionally to the ADAP budget was associated with delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued assessment of the role of ADAPs and their features that facilitate prompt treatment is needed. Public Library of Science 2013-11-18 /pmc/articles/PMC3832515/ /pubmed/24260137 http://dx.doi.org/10.1371/journal.pone.0078952 Text en © 2013 Hanna et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Collier, Ann Samji, Hasina Thorne, Jennifer E. Althoff, Keri N. Martin, Jeffrey N. Rodriguez, Benigno Stuart, Elizabeth A. Gange, Stephen J. Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title | Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title_full | Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title_fullStr | Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title_full_unstemmed | Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title_short | Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 |
title_sort | association between u.s. state aids drug assistance program (adap) features and hiv antiretroviral therapy initiation, 2001–2009 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832515/ https://www.ncbi.nlm.nih.gov/pubmed/24260137 http://dx.doi.org/10.1371/journal.pone.0078952 |
work_keys_str_mv | AT hannadavidb associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT buchaczkate associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT gebokellya associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT hessolnancya associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT horbergmichaela associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT jacobsonlisap associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT kirkgregoryd associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT kitahatamarim associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT korthuisptodd associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT moorerichardd associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT napravniksonia associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT patelpragna associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT silverbergmichaelj associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT sterlingtimothyr associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT willigjamesh associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT collierann associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT samjihasina associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT thornejennifere associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT althoffkerin associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT martinjeffreyn associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT rodriguezbenigno associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT stuartelizabetha associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT gangestephenj associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 AT associationbetweenusstateaidsdrugassistanceprogramadapfeaturesandhivantiretroviraltherapyinitiation20012009 |